InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,071.63
(
0.02%
)
US TECH 100
16,867.60
(
-0.80%
)
Dow Jones
38,460.92
(
-0.11%
)
Brent Oil
87.30
(
0.09%
)
Bitcoin
64,162.13
(
-0.19%
)
Post# of 251590
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119469
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 184934

Sunday, 12/21/2014 2:09:24 PM

Sunday, December 21, 2014 2:09:24 PM

Post# of 251590
When ENTA collects another $75M milestone for formal EU approval of Viekirax/Exviera* in January or February (#msg-108396853), ENTA’s cash balance will soar to the $250-300M range without even counting royalties (#msg-108457656).

*The EU brand names for the Viekira Pak constituent drugs.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up